ITMI960133A1 - GASTRORESISTANT PHARMACEUTICAL FORMULATIONS CONTAINING COLOSTRUM AND USE OF COLOSTRUM FOR THE TREATMENT OF ERECTILE DYSFUNCTIONS - Google Patents
GASTRORESISTANT PHARMACEUTICAL FORMULATIONS CONTAINING COLOSTRUM AND USE OF COLOSTRUM FOR THE TREATMENT OF ERECTILE DYSFUNCTIONS Download PDFInfo
- Publication number
- ITMI960133A1 ITMI960133A1 IT96MI000133A ITMI960133A ITMI960133A1 IT MI960133 A1 ITMI960133 A1 IT MI960133A1 IT 96MI000133 A IT96MI000133 A IT 96MI000133A IT MI960133 A ITMI960133 A IT MI960133A IT MI960133 A1 ITMI960133 A1 IT MI960133A1
- Authority
- IT
- Italy
- Prior art keywords
- colostrum
- treatment
- pharmaceutical formulations
- gastro
- erectile dysfunctions
- Prior art date
Links
- 210000003022 colostrum Anatomy 0.000 title claims abstract description 22
- 235000021277 colostrum Nutrition 0.000 title claims abstract description 22
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 7
- 230000004064 dysfunction Effects 0.000 title description 3
- 230000001856 erectile effect Effects 0.000 title description 2
- 201000001881 impotence Diseases 0.000 claims abstract description 10
- 238000009472 formulation Methods 0.000 claims abstract description 9
- 239000000203 mixture Substances 0.000 claims abstract description 9
- 208000010228 Erectile Dysfunction Diseases 0.000 claims abstract description 7
- 241000283073 Equus caballus Species 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 241000283690 Bos taurus Species 0.000 claims description 3
- 239000011049 pearl Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 235000008476 powdered milk Nutrition 0.000 claims 1
- 241001465754 Metazoa Species 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
- 210000003899 penis Anatomy 0.000 description 2
- 229940124549 vasodilator Drugs 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010002261 Androgen deficiency Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000023783 Genitourinary tract disease Diseases 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- 206010056303 Painful erection Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 239000002160 alpha blocker Substances 0.000 description 1
- 229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 description 1
- -1 amphetamines Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000005226 corpus cavernosum Anatomy 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 229960001789 papaverine Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 1
- 229960001999 phentolamine Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000003236 psychic effect Effects 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Formulazioni farmaceutiche gastroresistenti a base di colostro animale per il trattamento di disfunzioni erettili, e l'uso del colostro per il trattamento di disfunzioni erettili.Pharmaceutical gastro-resistant formulations based on animal colostrum for the treatment of erectile dysfunctions, and the use of colostrum for the treatment of erectile dysfunctions.
Description
Descrizione dell'invenzione industriale avente per titolo: "FORMULAZIONI FARMACEUTICHE GASTRORESISTENTI CONTENENTI COLOSTRO E USO DEL COLOSTRO PER IL TRATTAMENTO DI DISFUNZIONI ERETTILI" Description of the industrial invention entitled: "GASTRORESISTANT PHARMACEUTICAL FORMULATIONS CONTAINING COLOSTRUM AND USE OF COLOSTRUM FOR THE TREATMENT OF ERECTILE DYSFUNCTIONS"
La presente invenzione ha per oggetto formulazioni farmaceutiche gastroresistenti a base di colostro animale per il trattamento di disfunzioni erettili, e l'uso del colostro per il trattamento di disfunzioni erettili. The present invention relates to gastro-resistant pharmaceutical formulations based on animal colostrum for the treatment of erectile dysfunctions, and the use of colostrum for the treatment of erectile dysfunctions.
L'inpotenza è una disfunzione che consiste nella incapacità di ottenere o mantenere l'erezione del pene. Potency is a dysfunction consisting of the inability to obtain or maintain an erection of the penis.
I fattori eziologici dell'inpotenza possono essere organici (carenza di androgeni; malattie del tratto genito-urinario; diabete mellito; tossicomania e alcolismo; disturbi vascolari, locali o neurogenici; uso di antiipertensivi, amfetamine, tranquillanti e sedativi), o psichici (disturbi emotivi e psicotici, stress, ansia, depressione). The etiological factors of potency can be organic (androgen deficiency; genitourinary tract diseases; diabetes mellitus; drug addiction and alcoholism; vascular, local or neurogenic disorders; use of antihypertensives, amphetamines, tranquilizers and sedatives), or psychic (disorders emotional and psychotic, stress, anxiety, depression).
La terapia dipende principalmente dall'origine dell'impotenza: il trattamento può essere chirurgico (protesi che vengono impiantate nel pene o nel sacco scrotale per stimolare elettricamente i nervi erigentes) o farmacologico (iniezione nei corpi cavernosi di vasodilatatori, come la papaverina o di agenti α-bloccanti, come la fentolammina; applicazione topica di vasodilatatori come il minoxidil). Therapy mainly depends on the origin of impotence: treatment can be surgical (prostheses that are implanted in the penis or scrotal sac to electrically stimulate the erigent nerves) or pharmacological (injection into the corpora cavernosa of vasodilators, such as papaverine or other agents α-blockers, such as phentolamine; topical application of vasodilators such as minoxidil).
Ovviamente il paziente non è particolarmente favorevole all'approccio di tipo chirurgico; d'altra parte, anche il trattamento farmacologico non risulta particolarmente attraente, sia in considerazione della sede in cui deve essere iniettato il farmaco (dal medico o per auto-somministrazione), sia per gli effetti collaterali sgradevoli (rischio di erezione prolungata e dolorosa o di sovradosaggio). Obviously the patient is not particularly in favor of the surgical approach; on the other hand, even the drug treatment is not particularly attractive, both in consideration of the site where the drug must be injected (by the doctor or for self-administration), and for the unpleasant side effects (risk of prolonged and painful erection or of overdose).
Pertanto è fortemente sentita l'esigenza di un farmaco facilmente somministrabile, che induca l'erezione senza provocare gli effetti collaterali sopra indicati. Therefore, the need is strongly felt for a drug that can be easily administered, which induces an erection without causing the side effects indicated above.
La presente invenzione ha lo scopo di superare i problemi sopra indicati, mediante l'uso di formulazioni farmaceutiche gastroresistenti contenenti colostro equino o bovino o comunque di mammifero, ma preferibilmente equino,per indurre l'erezione. The present invention has the purpose of overcoming the problems indicated above, by using gastro-resistant pharmaceutical formulations containing equine or bovine or in any case mammalian colostrum, but preferably equine, to induce an erection.
La presente invenzione, inoltre, ha per oggetto l'uso di colostro equino o bovino o comunque di mammifero, ma preferibilmente equino, nel trattamento di disfunzioni erettili. Furthermore, the present invention relates to the use of equine or bovine or in any case mammalian colostrum, but preferably equine, in the treatment of erectile dysfunctions.
E' stato sorprendentemente trovato che il colostro, somministrato a pazienti affetti da impotenza, agisce favorevolmente inducendo l'erezione. It has been surprisingly found that colostrum, administered to patients suffering from impotence, acts favorably by inducing an erection.
Nella sperimentazione clinica, infatti, si è osservato che su 30 pazienti affetti da impotenza trattati, 25 rispondevano positivamente al trattamento con colostro, ottenendo un'erezione durevole e soddisfacente. In fact, in the clinical trial, it was observed that out of 30 treated impotence patients, 25 responded positively to colostrum treatment, obtaining a long-lasting and satisfactory erection.
Le formulazioni farmaceutiche gastroresistenti dell'invenzione contengono colostro in polvere o liquido in quantità da 500 mg a 5 g per dose unitaria. The gastro-resistant pharmaceutical formulations of the invention contain colostrum in powder or liquid form in quantities ranging from 500 mg to 5 g per unit dose.
Più particolarmente, le formulazioni dell'invenzione comprendono compresse gastroresistenti contenenti colostro in polvere, liofilizzato O sprayzzato, oppure perle gastroresistenti contenenti colostro liquido. More particularly, the formulations of the invention comprise gastro-resistant tablets containing powdered, freeze-dried or sprayed colostrum, or gastro-resistant pearls containing liquid colostrum.
Le conpresse o perle gastroresistenti dell'invenzione vengono preparate secondo le tecniche farmaceutiche convenzionali per la preparazione di formulazioni gastroresistenti. The gastro-resistant tablets or pearls of the invention are prepared according to conventional pharmaceutical techniques for the preparation of gastro-resistant formulations.
Le formulazioni dell'invenzione saranno assunte dal paziente affetto da inpotenza prima del rapporto sessuale. The formulations of the invention will be taken by the patient suffering from potency before sexual intercourse.
Secondo un ulteriore aspetto dell'invenzione, le formulazioni possono contenere colostro miscelato a latte. According to a further aspect of the invention, the formulations can contain colostrum mixed with milk.
Claims (7)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT96MI000133A IT1282953B1 (en) | 1996-01-26 | 1996-01-26 | GASTRO-RESISTANT PHARMACEUTICAL FORMULATIONS CONTAINING COLOSTRUM AND USE OF COLOSTRUM FOR THE TREATMENT OF ERECTILE DYSFUNCTIONS |
| PCT/EP1997/000331 WO1997026900A1 (en) | 1996-01-26 | 1997-01-24 | Gastro-resistant pharmaceutical formulations containing colostrum and the use of colostrum for the treatment of erectile dysfunctions |
| AU14450/97A AU1445097A (en) | 1996-01-26 | 1997-01-24 | Gastro-resistant pharmaceutical formulations containing colostrum and the use of colostrum for the treatment of erectile dysfunctions |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT96MI000133A IT1282953B1 (en) | 1996-01-26 | 1996-01-26 | GASTRO-RESISTANT PHARMACEUTICAL FORMULATIONS CONTAINING COLOSTRUM AND USE OF COLOSTRUM FOR THE TREATMENT OF ERECTILE DYSFUNCTIONS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| ITMI960133A0 ITMI960133A0 (en) | 1996-01-26 |
| ITMI960133A1 true ITMI960133A1 (en) | 1997-07-26 |
| IT1282953B1 IT1282953B1 (en) | 1998-04-02 |
Family
ID=11373032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IT96MI000133A IT1282953B1 (en) | 1996-01-26 | 1996-01-26 | GASTRO-RESISTANT PHARMACEUTICAL FORMULATIONS CONTAINING COLOSTRUM AND USE OF COLOSTRUM FOR THE TREATMENT OF ERECTILE DYSFUNCTIONS |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU1445097A (en) |
| IT (1) | IT1282953B1 (en) |
| WO (1) | WO1997026900A1 (en) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5742629A (en) * | 1980-08-29 | 1982-03-10 | Sendai Biseibutsu Kenkyusho | Remedy for refractory diseases |
| DK0675708T3 (en) * | 1993-01-26 | 1997-10-20 | Horse Vitality Ltd | Pharmaceutical and dermocosmetic compositions containing equine colostrum. |
-
1996
- 1996-01-26 IT IT96MI000133A patent/IT1282953B1/en active IP Right Grant
-
1997
- 1997-01-24 WO PCT/EP1997/000331 patent/WO1997026900A1/en active Application Filing
- 1997-01-24 AU AU14450/97A patent/AU1445097A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ITMI960133A0 (en) | 1996-01-26 |
| WO1997026900A1 (en) | 1997-07-31 |
| AU1445097A (en) | 1997-08-20 |
| IT1282953B1 (en) | 1998-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Waldhauser et al. | Efficiency and side effects of prostaglandin El in the treatment of erectile dysfunction | |
| US5891842A (en) | Methodology for eliciting an analgesic response in a living subject | |
| JP2011526889A (en) | Local nerve action therapy | |
| DE60022021D1 (en) | Preparations containing apomorphine and sildenafil and their use for the treatment of erectile dysfunction | |
| CA2269947A1 (en) | Covalent polar lipid conjugates for targeting | |
| PL334656A1 (en) | Dosage forms and methods of achieving betterement in cases of erection disorderamong male patients | |
| GB2316004A (en) | Novel formulations for transdermal delivery of pergolide | |
| IL135835A0 (en) | Novel conjugates of opioids and endogenous carriers | |
| BR0308137A (en) | Constant Release Drug Formulations Containing a Vehicle Peptide | |
| Sorbera et al. | IC-351 | |
| US6809079B2 (en) | Compositions and methods for treating female sexual arousal disorder using hydrophobic-calcitonin gene related peptide | |
| ES2268869T3 (en) | USE OF APOMORPHINE IN THE EFFECTIVE EYACULATION TREATMENT. | |
| RU2099078C1 (en) | Agent showing antistress, stress-protecting, nootropic, antialcoholic, antinarcotic effect, methods of prophylaxis and treatment using thereof | |
| Benkert | Studies on pituitary hormones and releasing hormones in depression and sexual impotence | |
| WO2003079976A3 (en) | A substance with sedative effect | |
| ITMI960133A1 (en) | GASTRORESISTANT PHARMACEUTICAL FORMULATIONS CONTAINING COLOSTRUM AND USE OF COLOSTRUM FOR THE TREATMENT OF ERECTILE DYSFUNCTIONS | |
| Ceccherelli et al. | Analgesic effect of subcutaneous administration of oxygen-ozone. A blind study in the rat on the modulation of the capsaicin-induced edema | |
| WO2017143119A1 (en) | Topical anorgasmia therapy | |
| WO2005049053A1 (en) | Composition comprising a magnesium compound and/or a magnesium saltfor improving sexual dysfunction | |
| Yap et al. | Topical agents and erectile dysfunction: is there a place? | |
| JP2000500159A (en) | Painkillers combined with melatonin | |
| KR20010076961A (en) | A medicament for prevention and treatment of sexual dysfunction | |
| Holaday et al. | Possible Function of β Endorphin | |
| Mora et al. | Evidence for an involvement of acetylcholine in self-stimulation of the prefrontal cortex in the rat | |
| CA2409592A1 (en) | Pharmceutical compositions comprising vip-related peptides for the treatment of sexual disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 0001 | Granted |